Seres Therapeutics Stock Forecast, Price & News

Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

Is Seres Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Seres Therapeutics stock.
View analyst ratings for Seres Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Seres Therapeutics?

Wall Street analysts have given Seres Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Seres Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Seres Therapeutics.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) announced its quarterly earnings results on Tuesday, August, 3rd. The biotechnology company reported ($0.53) EPS for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.12. The biotechnology company earned $5.26 million during the quarter, compared to analyst estimates of $4.40 million. Seres Therapeutics had a negative net margin of 441.65% and a negative trailing twelve-month return on equity of 87.12%.
View Seres Therapeutics' earnings history.

How has Seres Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MCRB stock has increased by 162.9% and is now trading at $6.94.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MCRB?

7 Wall Street analysts have issued 12 month price targets for Seres Therapeutics' stock. Their forecasts range from $7.00 to $32.00. On average, they anticipate Seres Therapeutics' share price to reach $20.83 in the next year. This suggests a possible upside of 200.2% from the stock's current price.
View analysts' price targets for Seres Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the following people:

• Eric D. Shaff, President, Chief Executive Officer & Director
• David A. Arkowitz, EVP, Chief Financial & Accounting Officer
• Matthew R. Henn, Chief Scientific Officer & Executive VP
• Barbara McGovern, Vice President-Medical Affairs
• Kelly M. Brady, Vice President-Clinical Operations

Who are some of Seres Therapeutics' key competitors?

Some companies that are related to Seres Therapeutics include Cassava Sciences (SAVA), ATA (ATAI), Taro Pharmaceutical Industries (TARO), Corcept Therapeutics (CORT), Morphic (MORF), Erasca (ERAS), Ligand Pharmaceuticals (LGND), IGM Biosciences (IGMS), Verve Therapeutics (VERV), Dynavax Technologies (DVAX), Ironwood Pharmaceuticals (IRWD), Myovant Sciences (MYOV), Indivior (INVVY), Harmony Biosciences (HRMY) and Amarin (AMRN).
View all of MCRB's competitors.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), The Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Flagship Pioneering Inc. (15.68%), FMR LLC (14.09%), ARK Investment Management LLC (10.59%), BlackRock Inc. (7.00%), Sumitomo Mitsui Trust Holdings Inc. (5.77%) and Nikko Asset Management Americas Inc. (5.76%).
View institutional ownership trends for Seres Therapeutics.

Which major investors are selling Seres Therapeutics stock?

MCRB stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Federated Hermes Inc., Flagship Pioneering Inc., Goldman Sachs Group Inc., Squarepoint Ops LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Seres Therapeutics or view top insider-selling stocks.

Which major investors are buying Seres Therapeutics stock?

MCRB stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., FMR LLC, Morgan Stanley, Morgan Stanley, BlackRock Inc., Lord Abbett & CO. LLC, Integral Health Asset Management LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Seres Therapeutics or or view top insider-buying stocks.

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $6.94.

How much money does Seres Therapeutics make?

Seres Therapeutics has a market capitalization of $636.53 million and generates $33.22 million in revenue each year. The biotechnology company earns $-89,130,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How many employees does Seres Therapeutics have?

Seres Therapeutics employs 155 workers across the globe.

What is Seres Therapeutics' official website?

The official website for Seres Therapeutics is www.serestherapeutics.com.

Where are Seres Therapeutics' headquarters?

Seres Therapeutics is headquartered at 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 945-9626 or via email at [email protected].